Literature DB >> 7669566

Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies.

H Messmann1, P Mlkvy, G Buonaccorsi, C L Davies, A J MacRobert, S G Bown.   

Abstract

5-Aminolaevulinic acid (ALA)-induced prophyrin photosensitisation is an attractive option for photodynamic therapy (PDT) since skin photosensitivity is limited to 1-2 days. However, early clinical results on colon tumours using the maximum tolerated oral dose of 60 mg kg-1 showed only superficial necrosis, presumably owing to insufficient intratumoral porphyrin levels, although inadequate light dosimetry may also be a factor. We undertook experiments using ALA, 25-400 mg kg-1 intravenously, to establish the threshold doses required for a PDT effect. Laser light at 630 nm (100 mW, 10-200 J) was delivered to a single site in the colon of photosensitised normal Wistar rats at laparotomy. The animals were killed 3 days later and the area of PDT-induced necrosis measured. No lesion was seen with 25 mg kg-1. The lesion size increased with larger ALA doses and with the light dose but little benefit was seen from increasing the ALA dose above 200 mg kg-1 or the light dose above 100 J. Thus there is a fairly narrow window for optimum doses of drug and light. Further experiments showed that the PDT effect can be markedly enhanced by fractionating the light dose. A series of animals was sensitized with 200 mg kg-1 ALA and then treated with 25 J. With continuous irradiation, the lesion area was 13 mm2, but with a single interruption of 150 s the area rose to 94 mm2 with the same total energy. Results were basically similar for different intervals between fractions (10-900 s) and different numbers of fractions (2-25). This suggests that a single short interruption in the light irradiation may dramatically reduce the net light dose required to achieve extensive necrosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669566      PMCID: PMC2033889          DOI: 10.1038/bjc.1995.378

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid.

Authors:  W E Grant; C Hopper; A J MacRobert; P M Speight; S G Bown
Journal:  Lancet       Date:  1993-07-17       Impact factor: 79.321

2.  Endogenous porphyrin distribution induced by 5-aminolaevulinic acid in the tissue layers of the gastrointestinal tract.

Authors:  C S Loh; D Vernon; A J MacRobert; J Bedwell; S G Bown; S B Brown
Journal:  J Photochem Photobiol B       Date:  1993-09       Impact factor: 6.252

3.  In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins.

Authors:  K König; H Schneckenburger; A Rück; R Steiner
Journal:  J Photochem Photobiol B       Date:  1993-05       Impact factor: 6.252

Review 4.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy.

Authors:  J C Kennedy; R H Pottier
Journal:  J Photochem Photobiol B       Date:  1992-07-30       Impact factor: 6.252

5.  Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response.

Authors:  K S McMahon; T J Wieman; P H Moore; V H Fingar
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

6.  Tumour destruction and proliferation kinetics following periodic, low power light, haematoporphyrin oligomers mediated photodynamic therapy in the mouse tongue.

Authors:  M B Pe; H Ikeda; T Inokuchi
Journal:  Eur J Cancer B Oral Oncol       Date:  1994-05

7.  Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid.

Authors:  C S Loh; J Bedwell; A J MacRobert; N Krasner; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

8.  In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: increased damage after multiple irradiations.

Authors:  N van der Veen; H L van Leengoed; W M Star
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

9.  Photodynamic therapy using 5-aminolaevulinic acid for experimental pancreatic cancer--prolonged animal survival.

Authors:  J Regula; B Ravi; J Bedwell; A J MacRobert; S G Bown
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

10.  Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

Authors:  C S Loh; A J MacRobert; J Bedwell; J Regula; N Krasner; S G Bown
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

View more
  18 in total

Review 1.  Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma.

Authors:  Harry Quon; Craig E Grossman; Jarod C Finlay; Timothy C Zhu; Clarice S Clemmens; Kelly M Malloy; Theresa M Busch
Journal:  Photodiagnosis Photodyn Ther       Date:  2011-06       Impact factor: 3.631

2.  Photodynamic therapy in gastroenterology.

Authors:  S G Bown; C E Millson
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

3. 

Authors:  C S Betz; A Leunig
Journal:  HNO       Date:  2004-02       Impact factor: 1.284

Review 4.  Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives.

Authors:  F S De Rosa; M V Bentley
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

5.  Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.

Authors:  Andrew Pye; Sandra Campbell; Alison Curnow
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-01       Impact factor: 4.553

6.  Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy.

Authors:  E Blake; J Allen; C Thorn; A Shore; A Curnow
Journal:  Lasers Med Sci       Date:  2012-08-28       Impact factor: 3.161

7.  Differences between cytotoxicity in photodynamic therapy using a pulsed laser and a continuous wave laser: study of oxygen consumption and photobleaching.

Authors:  S Kawauchi; Y Morimoto; S Sato; T Arai; K Seguchi; H Asanuma; M Kikuchi
Journal:  Lasers Med Sci       Date:  2004-01-31       Impact factor: 3.161

8.  Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC).

Authors:  P Mikvy; H Messman; A J MacRobert; M Pauer; V R Sams; C L Davies; J C Stewart; S G Bown
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo.

Authors:  P Babilas; V Schacht; G Liebsch; O S Wolfbeis; M Landthaler; R-M Szeimies; C Abels
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

Review 10.  Photodynamic Therapy-Current Limitations and Novel Approaches.

Authors:  Gurcan Gunaydin; M Emre Gedik; Seylan Ayan
Journal:  Front Chem       Date:  2021-06-10       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.